Regulus Therapeutics reported $11.66M in Current Liabilities for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Alnylam Pharmaceuticals ALNY:US USD 767.92M 4.88M
AstraZeneca AZN:LN USD 26.29B 1.44B
Astrazeneca AZN:US USD 26.29B 1.44B
Biogen BIIB:US USD 3.27B 653.6M
Celldex Therapeutics CLDX:US USD 18.61M 2.32M
Gilead Sciences GILD:US USD 11.24B 814M
GlaxoSmithKline GSK:LN GBP 22.81B 1.86B
Intercept Pharmaceuticals ICPT:US USD 230.08M 8.49M
Intrexon XON:US USD 78.64M 26.22M
Lexicon Pharmaceuticals LXRX:US USD 23.17M 4.73M
Ligand Pharmaceuticals LGND:US USD 98.81M 36.43M
Omeros OMER:US USD 136.38M 96.87M
Regulus Therapeutics RGLS:US USD 11.66M 1.14M
Sangamo Biosciences SGMO:US USD 111.71M 10.65M
Spectrum Pharmaceuticals SPPI:US USD 49.62M 8.58M
Takeda 4502:JP JPY 2.24T 154.91B
Vital Therapies VTL:US USD 13.08M 1.56M
YTE INCY:US USD 1.16B 150.48M